Skip to search formSkip to main contentSkip to account menu

HIV Protease Inhibitors [MoA]

Known as: HIV Protease Inhibitors, Human Immunodeficiency Virus Protease Inhibitors 
National Institutes of Health

Related topics

Related topics

27 relations
AmprenavirAtazanavirAtazanavir sulfateErgotamine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
Effect of Pregnancy on Cytochrome P450 3a and P-Glycoprotein Expression and Activity in the Mouse: Mechanisms, Tissue Specificity, and Time Course
The plasma concentrations of orally administered anti-human immunodeficiency virus protease inhibitors are significantly reduced… 
Highly Cited
2007
Highly Cited
2007
Effects of Human Immunodeficiency Virus Protease Inhibitors on the Intestinal Absorption of Tenofovir Disoproxil Fumarate In Vitro
ABSTRACT Human immunodeficiency virus protease inhibitors (PIs) modestly affect the plasma pharmacokinetics of tenofovir (TFV… 
Highly Cited
2007
Highly Cited
2007
Cytochrome P450 Enzymes and Transporters Induced by Anti-Human Immunodeficiency Virus Protease Inhibitors in Human Hepatocytes: Implications for Predicting Clinical Drug Interactions
Although many of the clinically significant drug interactions of the anti-human immunodeficiency virus (HIV) protease inhibitors… 
Highly Cited
2006
Highly Cited
2006
Potencies of Human Immunodeficiency Virus Protease Inhibitors In Vitro against Plasmodium falciparum and In Vivo against Murine Malaria
ABSTRACT Parasite resistance to antimalarial drugs is a serious threat to human health, and novel agents that act on enzymes… 
Highly Cited
2004
Highly Cited
2004
HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2)
Breast cancer resistance protein (BCRP) is a recently discovered ATP-binding cassette drug transporter. Hence, the full spectrum… 
Highly Cited
2003
Highly Cited
2003
Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models.
Highly Cited
2002
Highly Cited
2002
Intracellular Accumulation of Human Immunodeficiency Virus Protease Inhibitors
ABSTRACT Intracellular accumulation of the protease inhibitors (PIs) saquinavir (SQV), ritonavir (RTV), and indinavir (IDV) was… 
Highly Cited
2001
Highly Cited
2001
Use of Human Immunodeficiency Virus-1 Protease Inhibitors Is Associated With Atherogenic Lipoprotein Changes and Endothelial Dysfunction
Background—Human immunodeficiency virus protease inhibitors (HIV PIs) are associated with hyperlipidemia, hyperglycemia, and… 
Highly Cited
1999
Highly Cited
1999
In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors.
Highly active antiretroviral therapy that includes human immunodeficiency virus (HIV) aspartyl protease inhibitors (PIs) causes a… 
Highly Cited
1998
Highly Cited
1998
Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir *
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)